OKYO Pharma (OKYO) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed OKYO Pharma (OKYO) over the past year, gaining 2.0% versus a loss of 37.9%. PDS Biotechnology is the larger company by market cap ($89.9 million vs $72.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKYO | PDSB |
|---|---|---|
| Share price | $1.39 | $1.24 |
| Market cap | $72.95M | $89.87M |
| 1-day change | 0.00% | +21.57% |
| YTD return | -32.85% | +32.47% |
| 1-year return | -37.95% | +2.00% |
| 5-year return | — | -91.73% |
| EPS (TTM) | $-0.24 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $1.55 |
| 52-week low | $1.27 | $0.195 |
| Distance from 52-week high | -56.56% | -20.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +499.28% | +303.23% |
| Average volume | 93.79K | 23.24M |
| Shares outstanding | 52.48M | 72.47M |
| Employees | 5 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed OKYO by 39.9 percentage points over the past year.
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
OKYO vs PDSB FAQ
Which is bigger, OKYO Pharma or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $89.87M compared with $72.95M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, OKYO or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -37.95% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are OKYO Pharma and PDS Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for OKYO Pharma and Biotechnology: Pharmaceutical Preparations for PDS Biotechnology.